As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

The Peetes have turned Gemtesa promotion into a family business, with former professional quarterback Rodney Peete now ...

Despite the popularity of generic and biosimilar drugs in Europe—the latter of which have struggled to catch on in the ...

Thanks to his trusty Dexcom continuous glucose monitor (CGM), former boy band star Lance Bass is saying “bye bye bye” to ...

A new survey from Takeda due to be presented at the ESMO Gastrointestinal Cancers Congress in Spain this week highlights ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

Despite the slow trickle of updates on President Donald Trump’s proposed pharmaceutical import tariffs, drugmakers have ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

The Orphan Cures Act has been added back into the Senate version of President Donald Trump’s “big, beautiful bill” after being ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...